Skip to main content
Bimatoprost is easy to mix up because it has three separate stories. As an eye drop it is authorised across the EU to treat glaucoma. As an eyelash serum it is approved in some markets outside the EU. Used on the scalp for pattern hair loss, it is neither — Hi-Doctor’s doctors do not prescribe it for that.

​
What it is

Authorised across the EU under the brand Lumigan to lower pressure inside the eye in glaucoma and ocular hypertension.
Bimatoprost has no EU marketing authorisation for scalp hair loss. It may be an approved medicine for something else, or approved in another country — but not something a doctor here can prescribe for this.

​
How it works

Bimatoprost is a prostamide F2α analogue — a structural variant of prostaglandin F2α that is not a substrate for prostaglandin transporters or metabolic enzymes in the cornea. In the eye it acts on the prostaglandin F (FP) receptor in the ciliary muscle and trabecular meshwork, increasing aqueous humour outflow via the uveoscleral pathway, which reduces intraocular pressure. On the eyelid it is thought to prolong the anagen (growing) phase of the eyelash hair cycle by the same FP-receptor-mediated signalling, though the exact follicular mechanism is not fully established. The molecule has no sodium or potassium channel activity of its own; receptor activation triggers downstream mitogen-activated protein kinase (MAPK) pathways and upregulates hepatocyte growth factor (HGF) and other growth factors in dermal papilla cells.

​
What the studies reported

Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as a peer-reviewed publication.
The only trial behind bimatoprost’s use on the scalp is registry-posted results from a single six-month phase 2 study (NCT01904721, bimatoprost in men with androgenetic alopecia). The public record labels the concentrations only as “Solution 1” and “Solution 2” — there is no published, peer-reviewed readout, and bimatoprost holds no marketing authorisation for scalp hair loss in the EU or anywhere else.

​
What has been reported

These figures come from the EU-authorised eye-drop formulation (Lumigan), not from scalp use — there is no equivalent safety data for the scalp.

​
Available hair-growth alternatives

Because bimatoprost is not an option here, Hi-Doctor’s doctors review every case against the treatments that do have EU authorisation for hair loss:

Oral finasteride

A 5-alpha-reductase inhibitor taken daily. A doctor may prescribe it after reviewing your history and ruling out contraindications.

Oral minoxidil

Low-dose, used off-label by some dermatologists. Requires close medical supervision for potential cardiovascular effects.

Topical minoxidil

Solution or foam applied directly to the scalp. Can be combined with other actives in a compounded formulation.

Dutasteride 0.5mg

A more potent 5-alpha-reductase inhibitor. Reserved for specific cases, always under medical evaluation. See the dutasteride page.

Personalised compounded formulation

An individualised preparation that can combine finasteride, minoxidil, tretinoin, or other actives, compounded by pharmacies after a medical prescription.

​
How Hi-Doctor handles it

A licensed doctor decides case by case and never prescribes without an evaluation. For bimatoprost specifically, that means reviewing your hair growth questionnaire and proposing an equivalent treatment that does hold EU authorisation — such as topical minoxidil — rather than issuing a prescription for bimatoprost itself. See how a consultation works and the treatment areas Hi-Doctor covers.

​
Sources

  • EMA EPAR — Lumigan (bimatoprost eye drops), EMEA/H/C/000391, authorised in the EU for glaucoma and ocular hypertension
  • EMA — Lumigan product information (SmPC)
  • FDA label — LATISSE (bimatoprost ophthalmic solution) 0.03%, indicated for hypotrichosis of the eyelashes (US only)
  • ClinicalTrials.gov — NCT01904721, bimatoprost in men with androgenetic alopecia (results)

​
Start a consultation

Hair-growth consultation

Answer the hair-growth questionnaire and a registered doctor reviews it. They decide whether treatment is appropriate, which one, and at what dose — and declining is a normal outcome. See what it costs and how the review works.
This page is reference information, not medical advice and not a prescription. Whether a medicine is appropriate for you is decided by a registered doctor after reviewing your consultation.